CA2876689C — Substituted tricyclic compounds as fgfr inhibitors
Assigned to Incyte Holdings Corp · Expires 2022-04-26 · 4y expired
What this patent protects
The present invention relates to tricyclic compounds of formula I, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR- associated diseases such as cancer.
USPTO Abstract
The present invention relates to tricyclic compounds of formula I, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR- associated diseases such as cancer.
Drugs covered by this patent
- Pemazyre (PEMIGATINIB) · Incyte Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.